Population
A nationwide retrospective multicentric review of all pediatric cases
with OMT treated between January 2007 and December 2016 was conducted in
France. Eligible patients were females under 18 years of age at
diagnosis who underwent surgery for histologically proven OMT. Cases
were extracted by analyzing local and national databases of theSociété Française de lutte contre les Cancers et les leucémies de
l’Enfant (SFCE), the “Société Française de Chirurgie
pédiatrique ” (SFCP), the FrePSO (French Pediatric Surgeons Oncology)
group, the “Comité de Coordination de Pathologie Pédiatrique et
Périnatale ” (CCOPPP) and the FRACTURE (Groupe Français des
tumeurs rares ). Data on clinical features, imaging and laboratory
studies, surgical reports, pathological diagnoses and outcomes were
collected. Information on the management of second events and long-term
morbidity was also retrieved through the reports of the postoperative
consultations where abdominal ultrasound was carried out. In the absence
of consensus in the literature (17-19), the schedule of this follow-up
(FU) program differed from one center to another.
We defined persistent first complete remission (CR1) as patients who did
not experience any second event after initial surgery during the FU and
second (CR2) and third (CR3) complete remission as patients in remission
after one or two second events. A second event was considered when a new
ovarian mass, suggesting a new tumor, occurred in the same or in the
contralateral ovary after initial surgery. Pathological analysis should
be documented when a second surgery is carried out or highly suggestive
on imaging and biological work-up if the management is limited to
surveillance.